AACR Congratulates Dr. Raymond N. DuBois on His Appointment as Executive Director of Arizona State University’s Biodesign Institute
PHILADELPHIA — The American Association for Cancer Research congratulates Raymond N. DuBois, M.D., Ph.D., on his appointment as executive director of The Biodesign Institute at Arizona State University (ASU) in Tempe, Ariz. He will begin his new role on Dec. 1.
DuBois will also hold the Dalton Chair in ASU’s School of Health Solutions with joint appointments in chemistry and biochemistry, and will have a joint appointment at the Mayo Clinic where he will co-lead the cancer prevention program.
An internationally renowned physician-scientist, DuBois served as provost and executive vice president of The University of Texas MD Anderson Cancer Center in Houston since 2007. He also held appointments as professor of cancer biology and cancer medicine. At MD Anderson he was responsible for developing and overseeing research strategy, faculty, the School of Health Professions, graduate education programs and initiatives, and Global Academic Programs.
His groundbreaking research has helped increase our understanding of colorectal cancer, as he and colleagues were the first to discover that colorectal cancers over-expressed the enzyme cyclo-oxygenase-2 (COX-2) and that blocking or inhibiting COX-2 enzymes would shrink colorectal tumors. This research led to clinical trials involving Celebrex, a nonsteroidal anti-inflammatory drug used to treat arthritis, as a novel treatment for precancerous colorectal polyps.
“Dr. DuBois’ broad scientific expertise in basic, translational and clinical cancer research, as well as his vast administrative experience, will be a great asset to ASU and the Mayo Clinic,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “He is an internationally renowned scientist, an extraordinary leader in the field and a key member of the AACR whose vision will be of great value in his new position.”
“This opportunity gives me a chance to focus more of my energy on cancer research all the way from efficient delivery of care, to the development of more sustainable systems, to drug development using more refined approaches that include a deeper understanding of the biology and context of the drug targets,” DuBois said. “One of my goals is to catalyze important collaborations between ASU, the Translational Genomics Research Institute (TGen) and the Mayo Clinic in order to accelerate research progress. This will undoubtedly attract more funding from federal agencies and philanthropic support. I look forward to working with all of these groups to strengthen the overall cancer prevention programs in a way that has a measurable impact. Ultimately, I will work with the Biodesign team at ASU to develop a long-term strategic plan that encompasses efforts in life sciences, sustainability and security.”
DuBois received his bachelor’s degree in biochemistry from Texas A&M University in College Station, his doctorate in biochemistry from The University of Texas Southwestern Medical Center in Dallas and his medical degree from The University of Texas Health Science Center in San Antonio. Prior to joining MD Anderson, DuBois was the director of the Vanderbilt-Ingram Cancer Center in Nashville, Tenn., and director of the Division of Gastroenterology, Hepatology and Nutrition at Vanderbilt University, where he was also the B.F. Byrd Jr. Professor of Medical Oncology and professor of medicine, cell biology and cancer biology.
In addition to serving with distinction as AACR president from 2008-2009, DuBois served on the AACR Board of Directors prior to and during his presidency. He has served as chair of the AACR Think Tank, titled “AACR-NCI Think Tank: Charting the Future of Cancer Prevention,” and a chair and member of the AACR Executive Committee. He is current chair of the AACR Clinical and Translational Research Committee, a new initiative that will focus on ways to move this burgeoning field forward. He is also a member of AACR’s Science Policy and Legislative Affairs Committee and serves as a Trustee of the AACR Foundation for the Prevention and Cure of Cancer. He is a founding scientific advisor to Stand Up To Cancer (SU2C), for which the AACR serves as scientific partner, a prior member of the SU2C Scientific Advisory Committee, and now a member of the SU2C Management Committee. Among his other service to the AACR are his appointments as deputy editor of Cancer Prevention Research, associate editor of Cancer Research and as an editorial board member of Clinical Cancer Research, all journals of the AACR.
Throughout his career, DuBois has been honored extensively with accolades for his scientific achievements. He received the AACR-Richard and Hinda Rosenthal Foundation Award, the Dorothy P. Landon-AACR Prize for Translational Cancer Research, the Distinguished Achievement Award from the American Gastroenterological Association, the Ellen F. Knisely Distinguished Chair in Colon Cancer Research, the Johns Hopkins Society of Scholars, the E.V. Newman Research Prize from the Vanderbilt University Department of Medicine, the Anthony Dipple Carcinogenesis Award from Oxford University Press, the Outstanding Investigator Award from the American Federation for Medical Research and the Catedra Gonzalo Rio Arronte Award from Mexico City, Mexico.
DuBois is a fellow of the American Association for the Advancement of Science, serves on the executive committee of the Aspen Cancer Conference and is a founding scientific advisor for the National Colon Cancer Research Alliance. He is currently the principal investigator on a prevention program project grant from the National Cancer Institute.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.